ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • musculoskeletal sonography and symptoms
  • musculoskeletal sonography and systemic lupus erythematosus (SLE)
  • musculoskeletal sonography and utilization review
  • MWAS
  • Myalgic encephalomyelitis
  • Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  • Myasthenia Gravis
  • mycobacterium and rheumatoid arthritis (RA)
  • mycobacterium and spondylarthritis
  • mycobacterium and systemic lupus erythematosus (SLE)
  • mycophenolate mofetil
  • mycophenolate mofetil and meta-analysis
  • mycophenolate mofetil and outcomes
  • mycophenolate mofetil and pediatric rheumatology
  • mycophenolate mofetil and pediatrics
  • mycophenolate mofetil and pharmacokinetics
  • mycophenolate mofetil and pregnancy
  • mycophenolate mofetil and proteinuria
  • mycophenolate mofetil and systemic lupus erythematosus (SLE)
  • mycophenolate mofetil and systemic sclerosis
  • mycophenolate mofetil and tacrolimus
  • mycophenolate mofetil and therapy
  • mycophenolate mofetil and vasculitis
  • MyD88 and lupus nephritis
  • myelin oligodendrocyte glycoprotein
  • myeloid
  • Myeloperoxidase
  • myeloperoxidase (MPO)
  • myeloperoxidase (MPO) and polymorphism
  • myeloperoxidase (MPO) and vasculitis
  • Myocardial Infarction
  • myocardial infarction and outcomes
  • myocardial inflammation
  • Myocardial involvement
  • myocardial involvement and interferons
  • Myocardial involvement and myositis
  • myocardial involvement and pediatric rheumatology
  • myocardial involvement and pharmacotherapy
  • myocardial involvement and rheumatoid arthritis (RA)
  • myocardial involvement and systemic lupus erythematosus (SLE)
  • myocardial involvement and systemic sclerosis
  • myocardial involvement and vasculitis
  • Myocarditis
  • Myofibroblast
  • Myofibroblasts
  • myogenesis
  • myokines
  • Myopathies
  • myopathy
  • myopathy and myositis
  • myopathy and pediatrics
  • myopathy and pharmacology
  • myopathy and physical activity
  • myopathy and physical therapy
  • myopathy and polymyositis
  • myopathy and polymyositis/dermatomyositis (PM/DM)
  • myopathy and race/ethnicity
  • Myopathy and rituximab
  • myopathy and statins
  • myopathy and systemic sclerosis
  • Myositis
  • myositis and Idiopathis Inflammatory Myopathies (IIM)
  • myositis and immunology
  • myositis and interstitial lung disease
  • myositis and Musculoskeletal
  • myositis and natural killer (NK) cells
  • myositis and neroptosis
  • myositis and neutrophils
  • Myositis and outcome measures
  • Myositis and paraoxonase
  • Myositis and pathogenesis
  • myositis and patient outcomes
  • Myositis and patient-reported outcome measures
  • myositis and pediatric rheumatology
  • myositis and pediatrics
  • myositis and physical activity
  • myositis and polymyositis
  • myositis and polymyositis/dermatomyositis (PM/DM)
  • myositis and prognostic factors
  • Myositis and pulmonary complications
  • myositis and pulmonary fibrosis
  • myositis and quality of life
  • myositis and radiography
  • Myositis and randomized trials
  • myositis and registries
  • myositis and regulatory cells
  • myositis and risk assessment
  • myositis and rituximab
  • myositis and sarcoidosis
  • Myositis and scleroderma
  • myositis and scleroderma-like conditions
  • myositis and statin-induced myopathies
  • Myositis and statins
  • Myositis and stem cells
  • myositis and strength
  • myositis and synthetase syndrome
  • myositis and systemic lupus erythematosus (SLE)
  • myositis and systemic sclerosis
  • myositis and tacrolimus
  • myositis and therapeutic targeting
  • myositis and toll-like receptors
  • myositis and transcription factor
  • myositis and treatment
  • myositis and treatment options
  • myositis and ulcers
  • myositis and ultrasonography
  • Myositis and ultrasound
  • myositis and vasculitis
  • myositis and viruses
  • NAD+ booster
  • nail and joint damage
  • nail inflammation
  • nailfold capillaroscopy
  • nailfold capillaroscopy and Blood perfusion
  • nailfold capillaroscopy and clinical research
  • nailfold capillaroscopy and Disease Activity
  • nailfold capillaroscopy and pediatric rheumatology
  • nailfold capillaroscopy and pediatrics
  • nailfold capillaroscopy and pulmonary arterial hypertension
  • nailfold capillaroscopy and scleroderma
  • nailfold capillaroscopy and systemic sclerosis
  • Nailfold Capillary Microscopy
  • nanomedicine
  • nanomedicine and dexamethasone
  • nanomedicine and osteoarthritis
  • nanomedicine and rheumatoid arthritis
  • nanomedicine and rheumatoid arthritis (RA)
  • nanomedicine and systemic sclerosis
  • nanomedicine and transcriptional regulation
  • Nanostring and Interferon score
  • naproxen
  • naproxen and pain
  • nasal chondritis
  • nasopharyneal colonization
  • national program
  • Native American
  • Native Americans
  • Native Americans and inflammatory arthritis
  • natural history and disease burden
  • natural killer (NK) cells
  • natural killer (NK) cells and flow cytometry
  • natural killer (NK) cells and pathogenesis
  • natural killer (NK) cells and pediatric rheumatology
  • natural killer (NK) cells and polymorphism
  • Natural killer (NK) cells and rheumatoid arthritis (RA)
  • natural killer (NK) cells and signal transduction
  • natural killer (NK) cells and spondylarthropathy
  • natural killer (NK) cells and systemic lupus erythematosus (SLE)
  • Natural killer (NK) cells and systemic sclerosis
  • natural killer (NK) cells and tocilizumab
  • natural killer (NK) cells and toll-like receptors
  • Natural Killer Cell
  • Natural Killer Cells
  • natural language processing
  • Ncf1-R90H variant
  • nelfinavir and systemic lupus erythematosus
  • neonatal disorders
  • neonatal disorders and nod-like receptor (NLR)
  • neonatal disorders and pediatric rheumatology
  • neonatal disorders and registries
  • neonatal disorders and systemic lupus erythematosus (SLE)
  • neonatal disorders and transforming growth factor
  • Neonatal lupus
  • neonatal lupus and outcome measures
  • Neonatal lupus and outcomes
  • neonatal lupus and pathogenesis
  • Neonatal lupus and pregnancy
  • neonatal lupus and risk
  • Neonatal Lupus Erythematosus
  • neopterin
  • Nephritis
  • nephritis and mTOR pathway
  • nephritis and neutrophils
  • nephritis and pathogenesis
  • nephritis and pediatric rheumatology
  • nephritis and plasma cells
  • nephritis and pregnancy
  • nephritis and race/ethnicity
  • nephritis and skin
  • Nephritis and systemic lupus erythematosus (SLE)
  • nephritis and tolerance
  • nephritis and toll-like receptors
  • Nephritis and treatment
  • nephritis and vasculitis
  • nephrogenic fibrosing dermopathy and renal disease
  • nephropathy and biopsies
  • Nervous system lupus
  • nervous system lupus and pediatric rheumatology
  • nervous system lupus and renal disease
  • nervous system lupus and systemic lupus erythematosus (SLE)
  • nervous system lupus and T cells
  • NETosis
  • NETosis and antibody microarray
  • NETosis and Neutrophil Extracellular Traps
  • networking and primary care
  • networking and trainee
  • neural network and artificial intelligence
  • Neuroendocrine Immune (NEI)
  • Neuroendocrine Immune (NEI) and rheumatoid arthritis (RA)
  • Neuroimaging
  • First |
  • « Previous Page
  • 37
  • 38
  • 39
  • 40
  • 41
  • [42]
  • 43
  • 44
  • 45
  • 46
  • 47
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology